04:15 , Apr 13, 2018 |  BC Innovations  |  Targets & Mechanisms

Hello RNA

BioCentury’s analysis of new and emerging targets presented at this year’s AACR meeting reveals a surge in activity in non-coding RNAs, as researchers continue to expand target space. The results also reflect the ongoing high...
07:00 , Apr 23, 2015 |  BC Innovations  |  Translation in Brief

Funding faster diagnostics

Just two weeks after the White House released its National Action Plan for Combating Antibiotic Resistant Bacteria on March 27, NIH's National Institute of Allergy and Infectious Diseases (NIAID) announced it is awarding more than...
08:00 , Jan 7, 2013 |  BioCentury  |  Emerging Company Profile

Tolero: Pursuing proof of mechanism

Tolero Pharmaceuticals Inc. is using data from proof of mechanism studies to guide the go/no-go decisions for its pipeline of in-house and in-licensed cancer candidates. The platform-agnostic company expects to have its lead candidate in...
07:00 , May 7, 2012 |  BC Week In Review  |  Company News

Pfizer, Brigham Young University neurology, autoimmune news

Pfizer said it reached an "amicable" agreement with the university to settle a 2006 suit in the U.S. District Court for the District of Utah related to Celebrex celecoxib, a cyclooxygenase-2 (COX-2) inhibitor. As part...
08:00 , Dec 12, 2011 |  BioCentury  |  Emerging Company Profile

Sera Prognostics: Predicting preemies

Sera Prognostics Inc. is developing a molecular test that it thinks will accurately predict more than 90% of women at risk for preterm birth, allowing earlier monitoring and preventive treatment. The company raised $19.3 million...
07:00 , Jul 16, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Tubulin Total synthesis of celogentin C could help generate cancer therapeutics. Celogentin C, a derivative of plumed cockscomb (Celosia argentea) seeds, inhibits tubulin polymerization....
07:00 , May 26, 2008 |  BioCentury  |  Finance

Ebb & Flow

Based on its track record of exits from its BioDiscovery 1 and 2 funds during the last eight years, Edmond de Rothschild Investment Partners has raised a new E150 million ($233.8 million) fund in less...
07:00 , May 15, 2008 |  BC Innovations  |  Tools & Techniques

Barking Up the Right Tree

Researchers at Stanford University have developed a simple, scalable method for synthesizing the HIV drug candidates prostratin and its derivative 12-deoxyphorbol-13-phenylacetate that obviates the need to isolate prostratin from plant sources. The method, reported in...
07:00 , Apr 23, 2007 |  BioCentury  |  Emerging Company Profile

Wittycell: Outwitting the immune response

As vaccines become more targeted with regard to the antigens they use and more varied in the range of diseases they address, new adjuvants that can boost the immune response against a chosen antigen are...
07:00 , Apr 23, 2007 |  BioCentury  |  Emerging Company Profile

Corporate Profile

Wittycell S.A.S. Paris, France Technology: Adjuvants for prophylactic and therapeutic vaccines based on natural killer T cell stimulation Disease focus: None Clinical status: NA Founded: 2005 by Jacky Bernard, Vincent Serra and Philippe Pouletty University...